Vol. 6 No. 7 (2026): July
Reimbursement Reviews

Empagliflozin

decorative image of the issue cover

Published July 21, 2026

Key Messages

  • Reimbursement reviews of drugs later in the life cycle include a comprehensive assessment of clinical value, unmet clinical need, distinct social and ethical considerations, economic considerations, and impacts on the health systems.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial drug plans and cancer agencies.
  • This review assesses empagliflozin, 10 mg and 25 mg, oral tablets.
  • Indication under consideration for reimbursement: Treatment of CKD in adult patients.